Floatz logo

Zilovertamab

Lymphoma, Mantle-Cell

Oncternal Therapeutics, Incmonoclonal_antibodyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

172 Active assets in the Lymphoma, Mantle-Cell cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Busulphan
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Zilovertamab is also rated in:

lymphatic system disorderDormant
B
Indicative ·
60 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative ·
60 / 100
View asset →
immunoproliferative disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →